To gauge the effect of these market changes, Kesselheim and his colleagues conducted a retrospective cohort study
of approximately 217,000 commercially insured patients.
To gauge the impact of these market changes, Kesselheim and his colleagues conducted a retrospective cohort study
of close to 217,000 commercially insured patients.
The way this case was handled has led to a potentially useful drug, colchicine, being prescribed to fewer patients, while there have also been substantial cost increases for those who do use it and
no evidence of reductions in unsafe co-prescriptions,” says Kesselheim, in summarizing the findings.